Appointment of Joint Broker

RNS Number : 8217S

LungLife AI, INC

14 March 2023

 

LungLife AI, Inc.
(the "Company" or "LungLife")

Appointment of Joint Broker

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the appointment of Goodbody as the Company's Joint Broker with immediate effect.

Investec Bank plc remains Nominated Adviser and Joint Broker to the Company.

For further information please contact:

LungLife AI, Inc.	www.lunglifeai.com
Paul Pagano, CEO	Via Walbrook PR
David Anderson, CFO
Investec Bank plc (Nominated Adviser & J oint Broker)	Tel: [phone]
Virginia Bull / Cameron MacRitchie / Lydia Zychowska
Goodbody (Joint Broker) Tom Nicholson / Stephen Kane	Tel: [phone]
Walbrook PR Limited	Tel: [phone] or  [e-mail]
Stephanie Cuthbert / Alice Woodings / Phillip Marriage	Mob: [phone]

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

Our Purpose is to be a driving force in the early detection to lung cancer.  Our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.

 

END

 

 

APPSFAEFDEDSELD